SCHEMBL7182912

SCHEMBL7182912

Cc1cc(C)c(C(=O)Pc2ccc(OCc3ccccc3)cc2)c(C)c1.[LiH]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSPO P30536 2/20 0.51
MAOB P27338 1/20 0.48
PTGS1 P23219 2/20 0.48
PTGS2 P35354 2/20 0.48
LMNA P02545 2/20 0.48
CYP1A2 P05177 1/20 0.48
SLC6A2 P23975 1/20 0.48
CYP2C19 P33261 1/20 0.48
SLC6A3 Q01959 1/20 0.48
HIF1A Q16665 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
ALOX5 P09917 2/20 0.47
FFAR1 O14842 7/20 0.47
FFAR4 Q5NUL3 2/20 0.47
NR4A1 P22736 1/20 0.47
NR4A2 P43354 1/20 0.47
NR4A3 Q92570 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
PARP10 Q53GL7 1/20 0.45
MMP9 P14780 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185160 0.90 FFAR1 (0.50) MAOBPTGS1PTGS2LMNACYP1A2
SCHEMBL7186707 0.89 NR4A2 (0.50) TSPOMAOBPTGS1PTGS2LMNA
SCHEMBL7185643 0.88 MAOB (0.46) TSPOMAOBPTGS1PTGS2LMNA
SCHEMBL7188915 0.85 MAOB (0.48) TSPOMAOBALOX5FFAR1FFAR4
SCHEMBL7181059 0.83 MAOB (0.46) TSPOMAOBALOX5FFAR1FFAR4
SCHEMBL7181193 0.83 FFAR4 (0.45) TSPOMAOBALOX5FFAR1FFAR4
SCHEMBL7186887 0.83 ALDH1A1 (0.41) LMNACYP1A2PARP10
SCHEMBL7177267 0.83 SRD5A2 (0.41) PTGS1FFAR1FFAR4PARP10MMP9
SCHEMBL7179694 0.82 FFAR1 (0.45) MAOBPTGS1PTGS2LMNACYP1A2
Lithium SCHEMBL7181073 0.81 MAOB (0.46) TSPOMAOBALOX5FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TSPO 3188/4885MAOB 4189/4885PTGS1 3066/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TSPO 2597/4885MAOB 4319/4885PTGS1 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.